HRP20120490T1 - Spojevi za inhibiciju napredovanja mitoze - Google Patents
Spojevi za inhibiciju napredovanja mitoze Download PDFInfo
- Publication number
- HRP20120490T1 HRP20120490T1 HRP20120490TT HRP20120490T HRP20120490T1 HR P20120490 T1 HRP20120490 T1 HR P20120490T1 HR P20120490T T HRP20120490T T HR P20120490TT HR P20120490 T HRP20120490 T HR P20120490T HR P20120490 T1 HRP20120490 T1 HR P20120490T1
- Authority
- HR
- Croatia
- Prior art keywords
- aliphatic
- group
- fluoroaliphatic
- compound according
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 19
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 230000008600 mitotic progression Effects 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 14
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 10
- 125000005843 halogen group Chemical group 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- -1 -OH Chemical group 0.000 claims 6
- 102000003989 Aurora kinases Human genes 0.000 claims 5
- 108090000433 Aurora kinases Proteins 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- SRFVRJILPIASPG-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(1-methylpyrrol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2N(C=CC=2)C)=C1 SRFVRJILPIASPG-UHFFFAOYSA-N 0.000 claims 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims 1
- NRJOLMQQQLDIPP-UHFFFAOYSA-N 4-[[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#C)=C1 NRJOLMQQQLDIPP-UHFFFAOYSA-N 0.000 claims 1
- 102000004000 Aurora Kinase A Human genes 0.000 claims 1
- 108090000461 Aurora Kinase A Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- AIUYVPGHBMKGAC-UHFFFAOYSA-M sodium;4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoate Chemical compound [Na+].C1=C(C([O-])=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 AIUYVPGHBMKGAC-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Spoj formule I ili njegova farmaceutski prihvatljiva sol u kojem Ra je izabran iz grupe koju čine C alifatik C fluoroalifatik R T R R i T R T je C alkilen lanac izborno supstituiran sa fluoro R je ili člani aril heteroaril ili heterociklil prsten izborno supstituiran sa jednim ili dva supstituenta nezavisno izabrana iz grupe koju čine halo C alifatik i C fluoroalifatik R je izabran iz grupe koju čine halo C C R CH CH R N R i OR R je vodikC alifatik C fluoroalifatik ili CH OCH ili aril heteroaril ili heterociklil grupa svakoR nezavisno je vodik ili alifatična aril heteroaril ili heterociklil grupa ili dva R na istom atomu dušika zajedno sa atomom dušika formiraju do člani heteroaril ili do člani heterociklil prsten koji ima pored atoma dušika heteroatoma u prstenu izabrana od N O i S R je vodik C alifatična C fluoroalifatična ili aril heteroaril ili heterociklil grupa iRb je izabran iz grupe koju čine fluoro kloro CH CF OH OCH OCF OCH CH i OCH CF Patent sadržijoš patentnih zahtjeva
Claims (15)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol u kojem:
Ra je izabran iz grupe koju čine C1-3 alifatik, C1-3 fluoroalifatik, -R1, -T-R1, -R2 i -T-R2;
T je C1-3 alkilen lanac izborno supstituiran sa fluoro;
R1 je 5- ili 6-člani aril, heteroaril ili heterociklil prsten izborno supstituiran sa jednim ili dva supstituenta nezavisno izabrana iz grupe koju čine halo, C1-3 alifatik i C1-3 fluoroalifatik;
R2 je izabran iz grupe koju čine halo, -C≡C-R3, -CH=CH-R3, -N(R4)2 i -OR5;
R3 je vodik, C1-3 alifatik, C1-3 fluoroalifatik ili -CH2OCH3 ili aril, heteroaril, ili heterociklil grupa;
svako R4 nezavisno je vodik ili alifatična, aril, heteroaril ili heterociklil grupa; ili dva R4 na istom atomu dušika, zajedno sa atomom dušika formiraju 5- do 6-člani heteroaril ili 4- do 8-člani heterociklil prsten koji ima, pored atoma dušika, 0-2 heteroatoma u prstenu izabrana od N, O i S;
R5 je vodik, C1-3 alifatična, C1-3 fluoroalifatična ili aril, heteroaril ili heterociklil grupa; i
Rb je izabran iz grupe koju čine fluoro, kloro, -CH3, -CF3, -OH, -OCH3, -OCF3, -OCH2CH3 i -OCH2CF3.
2. Spoj prema patentnom zahtjevu 1, u kojem, Ra je halo, C1-3 alifatik, C1-3 fluoroalifatik, -OH, -O(C1-3 alifatik), -O(C1-3 fluoroalifatik) ili -C≡C-R3, -CH=CH-R3, pri čemu, R3 je vodik, C1-3 alifatik, C1-3 fluoroalifatik ili -CH2-OCH3;
ili Ra je fenil, furil, pirolidinil ili tienil prsten izborno supstituiran sa jednim ili dva supstituenta nezavisno izabrana iz grupe koju čine halo, C1-3 alifatik i C1-3 fluoroalifatik.
3. Spoj prema patentnom zahtjevu 2, u kojem je Ra izabran iz grupe koju čine kloro, fluoro, C1-3 alifatik, C1-3 fluoroalifatik, -OCH3, -OCF3, -C≡C-H, -C≡C-CH3, -C≡C-CH2OCH3, -CH=CH2, -CH=CHCH3, N-metilpirolidinil, tienil, metiltienil, furil, metilfuril, fenil, fluorofenil i tolil.
4. Spoj prema patentnom zahtjevu 1, naznačen time što, spoj je 4-{[9-etinil-7-(2-fluoro-6-metoksifenil)-5H-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoksibenzoeva kiselina ili njena farmaceutski prihvatljiva sol.
5. Spoj prema patentnom zahtjevu 1, naznačen time što, spoj je 4-{[7-(2-fluoro-6-metoksifenil)-9-(1-metil-1H-pirol-2-il)-5H-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoksibenzoeva kiselina ili njena farmaceutski prihvatljiva sol.
6. Spoj prema patentnom zahtjevu 1, naznačen time što, spoj je 4-{[9-kloro-7-(2-fluoro-6-metoksifenil)-5H-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoksibenzoeva kiselina ili njena farmaceutski prihvatljiva sol.
7. Spoj prema patentnom zahtjevu 1, naznačen time što, spoj je natrijev 4-{[9-kloro-7-(2-fluoro-6-metoksifenil)-5H-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoksibenzoat.
8. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1-7.
9. Farmaceutska kompozicija prema patentnom zahtjevu 8, koja sadrži farmaceutski prihvatljiv nosač i koja izborno dodatno sadrži drugo terapeutsko sredstvo.
10. In vitro postupak za inhibiciju aktivnosti Aurora kinaze u stanici, koji sadrži dovođenje u kontakt stanice u kojoj je poželjna inhibicija Aurora kinaze sa spojem prema bilo kojem od patentnih zahtjeva 1-7.
11. Postupak prema patentnom zahtjevu 8, naznačen time što, Aurora kinaza je Aurora A kinaza.
12. Spoj prema bilo kojem od patentnih zahtjeva 1-7 za upotrebu u liječenju poremećaja posredovanog preko Aurora kinaze.
13. Spoj prema patentnom zahtjevu 12, naznačen time što, poremećaj posredovan preko Aurora kinaze, je kancer.
14. Spoj prema patentnom zahtjevu 13, naznačen time što je kancer izabran iz grupe koju čine kolorektalni kancer, kancer jajnika, kancer dojke, kancer želudca, kancer prostate i kancer pankreasa.
15. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 7 u proizvodnji lijeka za liječenje kancera.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85934006P | 2006-11-16 | 2006-11-16 | |
| PCT/US2007/023948 WO2008063525A1 (en) | 2006-11-16 | 2007-11-14 | Compounds for inhibiting mitotic progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120490T1 true HRP20120490T1 (hr) | 2012-07-31 |
Family
ID=39315133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120490TT HRP20120490T1 (hr) | 2006-11-16 | 2012-06-12 | Spojevi za inhibiciju napredovanja mitoze |
| HRP20150047TT HRP20150047T1 (en) | 2006-11-16 | 2015-01-13 | Compound for inhibiting mitotic progression |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150047TT HRP20150047T1 (en) | 2006-11-16 | 2015-01-13 | Compound for inhibiting mitotic progression |
Country Status (35)
| Country | Link |
|---|---|
| US (6) | US8026246B2 (hr) |
| EP (4) | EP2497773B1 (hr) |
| JP (3) | JP5102839B2 (hr) |
| KR (2) | KR101110458B1 (hr) |
| CN (2) | CN103483343B (hr) |
| AR (1) | AR064246A1 (hr) |
| AT (1) | ATE556076T1 (hr) |
| AU (1) | AU2007322046B2 (hr) |
| BR (1) | BRPI0718803B8 (hr) |
| CA (1) | CA2669680C (hr) |
| CL (1) | CL2007003244A1 (hr) |
| CR (3) | CR10782A (hr) |
| CY (1) | CY1112828T1 (hr) |
| DK (2) | DK2086981T3 (hr) |
| EA (1) | EA015779B1 (hr) |
| ES (3) | ES2384123T3 (hr) |
| GE (1) | GEP20125459B (hr) |
| HK (4) | HK1134672A1 (hr) |
| HR (2) | HRP20120490T1 (hr) |
| IL (1) | IL198690A0 (hr) |
| MA (1) | MA30988B1 (hr) |
| MX (3) | MX343391B (hr) |
| MY (1) | MY153243A (hr) |
| NO (1) | NO343338B1 (hr) |
| NZ (3) | NZ577042A (hr) |
| PH (1) | PH12012502057A1 (hr) |
| PL (2) | PL2497772T3 (hr) |
| PT (2) | PT2086981E (hr) |
| RS (2) | RS53788B1 (hr) |
| SG (2) | SG176443A1 (hr) |
| SI (2) | SI2086981T1 (hr) |
| TW (1) | TWI401255B (hr) |
| UA (1) | UA94129C2 (hr) |
| WO (1) | WO2008063525A1 (hr) |
| ZA (1) | ZA200903279B (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4467616B2 (ja) | 2004-05-14 | 2010-05-26 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| AR074487A1 (es) * | 2008-12-05 | 2011-01-19 | Millennium Pharm Inc | Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer. |
| RU2535032C2 (ru) * | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| JP2013520424A (ja) * | 2010-02-19 | 2013-06-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| ES2526671T3 (es) * | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| TW201316991A (zh) | 2011-06-03 | 2013-05-01 | Millennium Pharm Inc | Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合 |
| US20130303519A1 (en) * | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN103772391A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN105209042B (zh) * | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| CA2972076A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| JP6955485B2 (ja) | 2015-09-09 | 2021-10-27 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| CA2997769A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| JP6591036B2 (ja) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| CA3017411A1 (en) | 2016-03-15 | 2017-09-21 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| JP6188986B1 (ja) * | 2017-03-23 | 2017-08-30 | 株式会社ノエビア | 時計遺伝子発現量調整剤及びエラスチン産生促進剤 |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| WO2023196959A1 (en) | 2022-04-07 | 2023-10-12 | Eli Lilly And Company | Process for making a kras g12c inhibitor |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| US20240108618A1 (en) | 2022-06-30 | 2024-04-04 | Eli Lilly And Company | Kras g12c inhibitor dosing regimens |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| IL59316A (en) | 1979-02-07 | 1983-07-31 | Sparamedica Ag | Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| CN1084747C (zh) * | 1996-03-08 | 2002-05-15 | 曾尼卡有限公司 | 作为神经活性剂的吡咯并苯并氮杂䓬衍生物 |
| JP2001507349A (ja) * | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| CN1155599C (zh) | 1997-09-29 | 2004-06-30 | 明治制果株式会社 | 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂 |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| ATE403644T1 (de) | 1999-12-06 | 2008-08-15 | Ajinomoto Kk | Amidinophenylbrenztraubensäure-derivat |
| MXPA03005610A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) * | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| MXPA04001252A (es) | 2001-08-09 | 2004-05-27 | Actelion Pharmaceuticals Ltd | Nuevos heterociclos benzo-fusionados como antagonistas de endotelina. |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| JP4467616B2 (ja) | 2004-05-14 | 2010-05-26 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| KR20070086188A (ko) | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | 키나제 억제제 |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| CN101389324A (zh) | 2005-12-23 | 2009-03-18 | 史密丝克莱恩比彻姆公司 | Aurora激酶的氮杂吲哚抑制剂 |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
-
2007
- 2007-11-09 CL CL200703244A patent/CL2007003244A1/es unknown
- 2007-11-14 RS RS20150047A patent/RS53788B1/en unknown
- 2007-11-14 EP EP12153134.7A patent/EP2497773B1/en active Active
- 2007-11-14 EP EP12153131.3A patent/EP2497772B1/en active Active
- 2007-11-14 US US11/985,277 patent/US8026246B2/en active Active
- 2007-11-14 GE GEAP200711309A patent/GEP20125459B/en unknown
- 2007-11-14 NZ NZ577042A patent/NZ577042A/en unknown
- 2007-11-14 KR KR1020097012501A patent/KR101110458B1/ko active IP Right Grant
- 2007-11-14 PT PT07867449T patent/PT2086981E/pt unknown
- 2007-11-14 RS RS20120247A patent/RS52313B/en unknown
- 2007-11-14 CN CN201310367332.9A patent/CN103483343B/zh active Active
- 2007-11-14 SG SG2011080652A patent/SG176443A1/en unknown
- 2007-11-14 MX MX2012011398A patent/MX343391B/es unknown
- 2007-11-14 DK DK07867449.6T patent/DK2086981T3/da active
- 2007-11-14 MY MYPI20091846A patent/MY153243A/en unknown
- 2007-11-14 JP JP2009537199A patent/JP5102839B2/ja active Active
- 2007-11-14 SG SG10201503350TA patent/SG10201503350TA/en unknown
- 2007-11-14 CA CA2669680A patent/CA2669680C/en active Active
- 2007-11-14 PT PT121531313T patent/PT2497772E/pt unknown
- 2007-11-14 SI SI200730975T patent/SI2086981T1/sl unknown
- 2007-11-14 PL PL12153131T patent/PL2497772T3/pl unknown
- 2007-11-14 NZ NZ597252A patent/NZ597252A/xx unknown
- 2007-11-14 WO PCT/US2007/023948 patent/WO2008063525A1/en active Application Filing
- 2007-11-14 SI SI200731591T patent/SI2497772T1/sl unknown
- 2007-11-14 BR BRPI0718803A patent/BRPI0718803B8/pt active IP Right Grant
- 2007-11-14 PL PL07867449T patent/PL2086981T3/pl unknown
- 2007-11-14 NZ NZ611898A patent/NZ611898A/en not_active IP Right Cessation
- 2007-11-14 ES ES07867449T patent/ES2384123T3/es active Active
- 2007-11-14 AU AU2007322046A patent/AU2007322046B2/en active Active
- 2007-11-14 MX MX2012011396A patent/MX348568B/es unknown
- 2007-11-14 ES ES12153131.3T patent/ES2528793T3/es active Active
- 2007-11-14 DK DK12153131.3T patent/DK2497772T3/en active
- 2007-11-14 MX MX2009004670A patent/MX2009004670A/es active IP Right Grant
- 2007-11-14 AT AT07867449T patent/ATE556076T1/de active
- 2007-11-14 CN CN2007800423837A patent/CN101547924B/zh active Active
- 2007-11-14 EP EP15155821.0A patent/EP2944639B1/en active Active
- 2007-11-14 EA EA200970486A patent/EA015779B1/ru unknown
- 2007-11-14 UA UAA200906211A patent/UA94129C2/ru unknown
- 2007-11-14 KR KR1020117022355A patent/KR101342014B1/ko active IP Right Grant
- 2007-11-14 ZA ZA200903279A patent/ZA200903279B/xx unknown
- 2007-11-14 ES ES12153134.7T patent/ES2537451T3/es active Active
- 2007-11-14 EP EP07867449A patent/EP2086981B1/en active Active
- 2007-11-14 TW TW096143087A patent/TWI401255B/zh active
- 2007-11-16 AR ARP070105104A patent/AR064246A1/es unknown
-
2009
- 2009-05-08 CR CR10782A patent/CR10782A/es unknown
- 2009-05-11 IL IL198690A patent/IL198690A0/en active IP Right Grant
- 2009-05-13 NO NO20091864A patent/NO343338B1/no unknown
- 2009-06-12 MA MA31985A patent/MA30988B1/fr unknown
-
2010
- 2010-02-11 HK HK10101590.0A patent/HK1134672A1/xx unknown
-
2011
- 2011-08-25 US US13/217,659 patent/US20110312942A1/en not_active Abandoned
- 2011-08-25 US US13/217,729 patent/US9988384B2/en active Active
- 2011-08-30 JP JP2011187930A patent/JP5452811B2/ja active Active
-
2012
- 2012-06-06 CY CY20121100518T patent/CY1112828T1/el unknown
- 2012-06-12 HR HRP20120490TT patent/HRP20120490T1/hr unknown
- 2012-10-12 PH PH12012502057A patent/PH12012502057A1/en unknown
-
2013
- 2013-03-08 HK HK13102944.8A patent/HK1175777A1/xx unknown
- 2013-03-11 HK HK13102986.7A patent/HK1175778A1/xx unknown
- 2013-11-15 JP JP2013236439A patent/JP2014055166A/ja active Pending
-
2014
- 2014-04-04 CR CR20140154A patent/CR20140154A/es unknown
- 2014-10-15 US US14/514,687 patent/US9765076B2/en active Active
- 2014-11-27 CR CR20140544A patent/CR20140544A/es unknown
-
2015
- 2015-01-13 HR HRP20150047TT patent/HRP20150047T1/hr unknown
-
2016
- 2016-05-17 HK HK16105677.1A patent/HK1217699A1/zh unknown
-
2018
- 2018-06-01 US US15/996,166 patent/US10836766B2/en active Active
-
2020
- 2020-11-16 US US17/099,266 patent/US11958855B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120490T1 (hr) | Spojevi za inhibiciju napredovanja mitoze | |
| CN101675053B (zh) | 磷酸肌醇3-激酶抑制剂化合物及使用方法 | |
| RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
| ES2970074T3 (es) | Inhibidor de ATR y su aplicación | |
| JP2010510215A5 (hr) | ||
| ES2668834T3 (es) | Pirimidinas macrociclicas como inhibidores de proteína quinasas | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| HRP20120785T1 (hr) | Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
| ATE361916T1 (de) | Pyrimidine verbindungen | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| CN102089312A (zh) | 作为蛋白酶体抑制剂的Salinosporamide衍生物 | |
| RU2341527C1 (ru) | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ | |
| EA201991025A1 (ru) | Липосомальный препарат для применения для лечения злокачественного новообразования | |
| RU2007125661A (ru) | Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина | |
| RU2005135338A (ru) | Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона | |
| CN103483345A (zh) | Pi3k 激酶抑制剂、包含其的药物组合物及其应用 | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| WO2010002779A2 (en) | Naphthyridininones as aurora kinase inhibitors | |
| JP2014524449A5 (hr) | ||
| RS51320B (sr) | Derivati imidazohinolina kao veznici a3 receptora adenozina | |
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет |